Minna Holopainen

Mrs. Minna Holopainen

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
KHKati Hyvärinen
Kati Hyvärinen
MHMinna Holopainen
Minna Holopainen
VSVita Skirdenko
Vita Skirdenko
HRHanna Ruhanen
Hanna Ruhanen
PLPetri Lehenkari
Petri Lehenkari
EKErja Kerkelä
Erja Kerkelä
Resolution-phase macrophage population orchestrates active dampening of the inflammation by secreting anti-inflammatory and proresolving products including interleukin (IL)-10 and lipid mediators (LMs). We investigated the effects of both human bone marrow-derived mesenchymal stromal cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) on mature human regulatory macrophages (Mregs). The cytokines and LMs were determined from cell culture media of Mregs cultivated with MSCs and MSC-EVs. In addition, the alterations in the expression of cell surface markers and the phagocytic ability of Mregs were investigated. Our novel findings indicate that both MSC coculture and MSC-EVs downregulated the production of IL-23 and IL-22 enhancing the anti-inflammatory phenotype of Mregs and amplifying proresolving properties. The levels of prostaglandin E2 (PGE2) were substantially upregulated in MSC coculture media, which may endorse proresolving LM class switching. In addition, our results manifest, for the first time, that MSC-EVs mediate the Mreg phenotype change via PGE2. These data suggest that both human MSC and MSC-EVs may potentiate tolerance-promoting proresolving phenotype of human Mregs.

8 May 2019 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
VJVadim Le Joncour
Vadim Le Joncour
PFPauliina Filppu
Pauliina Filppu
MHMaija Hyvönen
Maija Hyvönen
MHMinna Holopainen
Minna Holopainen
STS Pauliina Turunen
S Pauliina Turunen
PLPirjo Laakkonen
Pirjo Laakkonen
The current clinical care of glioblastomas leaves behind invasive, radio‐ and chemo‐resistant cells. We recently identified mammary‐derived growth inhibitor (MDGI/ FABP3 ) as a biomarker for invasive gliomas. Here, we demonstrate a novel function for MDGI in the maintenance of lysosomal membrane integrity, thus rendering invasive glioma cells unexpectedly vulnerable to lysosomal membrane destabilization. MDGI silencing impaired trafficking of polyunsaturated fatty acids into cells resulting in significant alterations in the lipid composition of lysosomal membranes, and subsequent death of the patient‐derived glioma cells via lysosomal membrane permeabilization (LMP). In a preclinical model, treatment of glioma‐bearing mice with an antihistaminergic LMP‐inducing drug efficiently eradicated invasive glioma cells and secondary tumours within the brain. This unexpected fragility of the aggressive infiltrating cells to LMP provides new opportunities for clinical interventions, such as re‐positioning of an established antihistamine drug, to eradicate the inoperable, invasive, and chemo‐resistant glioma cells from sustaining disease progression and recurrence.

1 October 2019 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
MHMinna Holopainen
Minna Holopainen
RCRomain A. Colas
Romain A. Colas
SVSami Valkonen
Sami Valkonen
FTFeven Tigistu-Sahle
Feven Tigistu-Sahle
KHKati Hyvärinen
Kati Hyvärinen
SLSaara Laitinen
Saara Laitinen

1 August 2019 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
SVSami Valkonen
Sami Valkonen
MHMinna Holopainen
Minna Holopainen
RCRomain A. Colas
Romain A. Colas
UIUlla Impola
Ulla Impola
JDJesmond Dalli
Jesmond Dalli
SLSaara Laitinen
Saara Laitinen

1 January 2017 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
FTFeven Tigistu-Sahle
Feven Tigistu-Sahle
MLMilla Lampinen
Milla Lampinen
LKLotta Kilpinen
Lotta Kilpinen
MHMinna Holopainen
Minna Holopainen
PLPetri Lehenkari
Petri Lehenkari
RKReijo Käkelä
Reijo Käkelä
High arachidonic acid (20:4n-6) and low n-3 polyunsaturated fatty acid (PUFA) levels impair the capacity of cultured human bone marrow mesenchymal stromal cells (hBMSCs) to modulate immune functions. Capacity of the hBMSCs to modify PUFA structures was found to be limited. Therefore different PUFA supplements given to the cells resulted in very different glycerophospholipid (GPL) species profiles and substrate availability for phospholipases, which have preferences for polar head group and acyl chains when liberating PUFA precursors for production of lipid mediators. When supplemented with 20:4n-6, the cells increased prostaglandin E2 secretion. However, they elongated 20:4n-6 to less active precursor 22:4n-6, and also incorporated it into triacylglycerols, which may have limited the proinflammatory signalling. The n-3 PUFA precursor 18:3n-3 had little potency to reduce the GPL 20:4n-6 content, while the eicosapentaenoic (20:5n-3) and docosahexaenoic (22:6n-3) acid supplements efficiently displaced the 20:4n-6 acyls, and created diverse GPL species substrate pools allowing to attenuate inflammatory signalling. The results emphasize the importance of choosing appropriate PUFA supplements for in vitro hBMSC expansion and suggests that for optimal function they require an exogenous fatty acid source providing sufficiently 20:5n-3 and 22:6n-3 but moderately 20:4n-6, which calls for specifically designed optimal PUFA supplements for the cultures.

22 September 2020 in Cells
Verified
Journal Article
Open access
PDF file
MHMinna Holopainen
Minna Holopainen
UIUlla Impola
Ulla Impola
PLPetri Lehenkari
Petri Lehenkari
SLSaara Laitinen
Saara Laitinen
EKErja Kerkelä
Erja Kerkelä
Human mesenchymal stromal/stem cells (hMSCs) show great promise in cell therapy due to their immunomodulatory properties. The overall immunomodulatory response of hMSCs resembles the resolution of inflammation, in which lipid mediators and regulatory macrophages (Mregs) play key roles. We investigated the effect of hMSC cell-cell contact and secretome on macrophages polarized and activated toward Mreg phenotype. Moreover, we studied the effect of supplemented polyunsaturated fatty acids (PUFAs): docosahexaenoic acid (DHA) and arachidonic acid, the precursors of lipid mediators, on hMSC immunomodulation. Our results show that unlike hMSC cell-cell contact, the hMSC secretome markedly increased the CD206 expression in both Mreg-polarized and Mreg-activated macrophages. Moreover, the secretome enhanced the expression of programmed death-ligand 1 on Mreg-polarized macrophages and Mer receptor tyrosine kinase on Mreg-activated macrophages. Remarkably, these changes were translated into improved Candida albicans phagocytosis activity of macrophages. Taken together, these results demonstrate that the hMSC secretome promotes the immunoregulatory and proresolving phenotype of Mregs. Intriguingly, DHA supplementation to hMSCs resulted in a more potentiated immunomodulation with increased CD163 expression and decreased gene expression of matrix metalloproteinase 2 in Mreg-polarized macrophages. These findings highlight the potential of PUFA supplementations as an easy and safe method to improve the hMSC therapeutic potential.